Molecular Templates (MTEM) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MTEM shares.
View MTEM analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1 year target prices for Molecular Templates' shares. Their MTEM share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 130.1% from the stock's current price.
View analysts price targets for MTEM or view top-rated stocks among Wall Street analysts.

Molecular Templates' stock was trading at $4.92 at the beginning of the year. Since then, MTEM stock has increased by 32.5% and is now trading at $6.52.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our MTEM earnings forecast.

Molecular Templates, Inc. (NASDAQ:MTEM) announced its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($3.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.25) by $1.95. The biotechnology company earned $6.87 million during the quarter. Molecular Templates had a negative net margin of 92.78% and a negative trailing twelve-month return on equity of 1,843.37%.

Molecular Templates's stock reverse split on the morning of Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MTEM stock can currently be purchased for approximately $6.52.

Molecular Templates (NASDAQ:MTEM) has a market capitalization of $35.08 million and generates $19.75 million in revenue each year. The biotechnology company earns $-92,720,000.00 in net income (profit) each year or ($12.4438) on an earnings per share basis.

The company employs 111 workers across the globe.

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The official website for the company is www.mtem.com. The biotechnology company can be reached via phone at (512) 869-1555, via email at adam.cutler@mtem.com, or via fax at 650-474-2529.